Margaretha Grind - Concepedia

Author

Margaretha Grind

AstraZeneca (Sweden)

Also Known As

M Grind, M. Grind, M. Groschinsky Grind, Margaretha Grind, Margaretha Groschinsky Grind

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (Sweden)Karolinska Institutet Birmingham City Hospital Loughborough University University of Vienna

About

Margaretha Grind is an author at AstraZeneca (Sweden) specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	340
2	Pharmacology	8	8	340
3	Psychiatry	2	2	49
4	Public Health	1	1	18
5	Nutrition	1	1	23

Margaretha Grind

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation Gregory W. Albers, Hans‐Christoph Diener, Lars Frison, JAMA	2005	662
Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation Palle Petersen, Margaretha Grind, John R. Adler Journal of the American College of Cardiology ThrombosisCardiovascular DiseaseStrokePharmacologyCardiovascular Pharmacology	2003	190
Effect of hypertension on anticoagulated patients with atrial fibrillation Gregory Y.H. Lip, Lars Frison, Margaretha Grind European Heart Journal	2007	167
Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation Gregory Y.H. Lip, Lars Frison, Margaretha Grind Journal of Internal Medicine	2008	57
Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects Michael Wolzt, Maria Wollbratt, Mia Svensson, European Journal of Clinical Pharmacology ThrombosisHealthy SubjectsCardiovascular DiseasePharmacologyCardiovascular Pharmacology	2003	40
Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism Gunnar Alván, Margaretha Grind, Christina Graffner, Clinical Pharmacology & Therapeutics	1984	32
Remoxipride ? a new potential antipsychotic drug Lars Farde, Margaretha Grind, Michael Nilsson, Psychopharmacology Psychoactive DrugPsychiatryMedicinePsychopharmacologyPharmacotherapy	1988	26
Prevalence of Markers of Heart Failure in Patients with Atrial Fibrillation and the Effects of Ximelagatran Compared to Warfarin on the Incidence of Morbid and Fatal Events: A Report from the SPORTIF III and V Trials John G.F. Cleland, Rhiddian Shelton, Nikolay P. Nikitin, European Journal of Heart Failure	2007	25
Decreased Oral Bioavailability of Lansoprazole in Healthy Volunteers when Given with a Standardised Breakfast Robert Bergstrand, Margaretha Grind, Gunnar Nyberg, Clinical Drug Investigation NutritionOral BioavailabilityMedicineGastrointestinal PharmacologyHealthy Volunteers	1995	23
Remoxipride ? a new potential antipsychotic compound Margaretha Grind, Maj‐Inger Nilsson, Lars Nilsson, Psychopharmacology Psychoactive DrugPsychiatryMedicinePsychopharmacologyPharmacotherapy	1989	23

Page 1